Objective: A single-agent topotecan has an indication for the treatment of small cell lung cancer in Japan. Previous studies demonstrated that topotecan combined with a platinum agent could provide additional antitumor efficacy. This study was to find the recommended dose of topotecan in combination with cisplatin and preferred administration sequence in untreated patients with extensive disease small cell lung cancer for Phase II study. Methods: Patients received topotecan as a 30 min infusion for 5 days in escalating doses (starting at 0.5 mg/m 2 /day), and cisplatin at a fixed dose of 60 mg/m 2 , 3 weeks cycle. This study employed the following stages: cisplatin was given before topotecan on day 1 to previously treated patients (Stage 1). After the maximum-tolerated dose level was achieved, the same schedule was applied for untreated patients (Stage 2). Subsequently, cisplatin was given after topotecan on day 5 to untreated patients (Stage 3). The recommended doses of cisplatin on day 1 and 5 schedules were estimated by considering results obtained from Stages 2 and 3, respectively. Results: A total of 34 patients were enrolled. The maximum-tolerated doses in Stages 1 -3 were estimated at 0.65, 0.65, and 1.4 mg/m 2 , respectively. The recommended doses of cisplatin on day 1 and 5 schedules in untreated patients were determined at 0.65 and 1.0 mg/m 2 , respectively. The major toxicity in this combination was hematological events. Conclusions: For treatment-naive patients, the combined use of 0.65/60 mg/m 2 topotecan/ cisplatin with cisplatin on day 1 schedule or 1.0/60 mg/m 2 topotecan/cisplatin with cisplatin on day 5 schedule is recommended for Phase II study.
INTRODUCTION
Small cell lung cancer (SCLC) is often diagnosed at the extensive disease (ED) stage due to lesion location and rapid disease progression (1) . Multiagent chemotherapy is the mainstay of treatment for SCLC, and combination regimens such as cisplatin þ etoposide are being used as the standard therapy for ED cases (2) . Topotecan, a topoisomerase-I inhibitor, has a favorable toxicity profile compared with most other agents that are active in SCLC. Topotecan has a well-characterized and predictable hematologic toxicity profile that includes neutropenia, which is manageable, short-lived and reversible. The non-hematologic effects of topotecan are generally mild and include manageable gastrointestinal toxicities (3) . A single-agent topotecan showed significant activity in SCLC, particularly in patients sensitive to prior chemotherapy; therefore, the incorporation of topotecan in combination chemotherapy regimens for the future treatment of SCLC was warranted (3) . Although single-agent topotecan has already an indication for the treatment of SCLC in Japan, previous preclinical and clinical studies have demonstrated that the combination of topotecan with a platinum agent, such as cisplatin, could provide additional antitumor efficacy (4 -9) . In addition, one study addressed the impact of cisplatin scheduling and showed that the sequence of cisplatin before topotecan induced significantly worse hematological toxicity than the alternate sequence (10) . To improve the therapeutic effect of this combination, the granulocyte colony-stimulating factor (G-CSF) was employed as concomitant therapy in our study.
Thus, we designed the present study to evaluate both administration sequences. The prime objective of the study was to determine the recommended dosage for a subsequent Phase II study from the estimation of maximum-tolerated dose (MTD) of topotecan in combination with 60 mg/m 2 cisplatin on day 1 or 5 in previously untreated patients with SCLC.
METHODS

ELIGIBILITY
Written informed consent was obtained from all patients prior to treatment. The protocol and informed consent procedures were reviewed and approved by the Institutional Review Board of each participating institute. Eligibility criteria were as follows: histologically or cytologically proven SCLC; 20 -74 years old; previously treated with singleregimen chemo-and/or radiotherapy, or previously untreated patients with ED; no prior treatment with biological response modifiers within 2 weeks; adequate organic function (hemoglobin level 9.5 g/dl, leukocyte count of 4000 -12 000/ mm 3 , neutrophil cell count 2000/mm 3 , platelet count 100 000/mm 3 , aspartate aminotransferase and alanine aminotransferase levels ,2.5 times the upper limit of normal, total bilirubin value ,1.5 mg/dl, serum creatinine below the upper limit of normal, partial pressure of arterial oxygen 60 mmHg); performance status of 0 -1 on the Eastern Cooperative Oncology Group scale; a life expectancy of at least 3 months; and hospitalized patients.
Exclusion criteria included the following: serious infection or other serious concurrent disease; massive pleural effusion or ascites; interstitial pneumonia or pulmonary fibrosis; symptomatic central nervous system metastasis; concomitant malignancies; patients who received bone marrow or peripheral blood stem cell transplantation; a past history of drug allergy; actual or potential pregnancy, breast-feeding status or the intention to become pregnant in the near future; poorly controlled diabetes; previously treated with topotecan; or any other condition that was considered to make the patient ineligible for this study by the investigator.
TREATMENT PLAN AND DOSE ESCALATION
This study employed the following three stages: Stage 1, cisplatin administration on day 1 followed by topotecan on days 1 -5 to previously treated patients; Stage 2, on the same schedule as Stage 1 to previously untreated patients; and Stage 3, topotecan administration on days 1 -5 followed by cisplatin on day 5 to previously untreated patients. The dose level of cisplatin was fixed at 60 mg/m 2 and the dose of topotecan was increased from 0.5 mg/m 2 followed by 0.65, 0.8, 1.0, 1.2 and 1.4 mg/m 2 . The stage was moved up to the next after the MTD level was achieved, and the MTD was used as the starting dose in the next stage. Topotecan was administrated by 30 min intravenous infusion for 5 consecutive days. Cisplatin dissolved in 500 -1000 ml of physiological saline was infused intravenously over 2 h either on day 1 ( prior to topotecan) or day 5 (subsequent to topotecan). Immediately before and after each administration of cisplatin, hydration consisting of 1000 -2000 ml of fluid infusion was given intravenously over 4 h. Treatment was repeated every 3 weeks and the next cycle could be expanded to a maximum of 35 days. At all dose levels of all stages, the prophylactic use of G-CSF was initiated from the next day of last administration of topotecan. G-CSF was administered till the recovery of leukocyte or neutrophil after nadir (recovery as either leukocyte count reached 10 000/mm 3 or neutrophil count reached 5000/mm 3 ). In the present study, dose-limiting toxicity (DLT) was defined as follows: Grade 4 neutropenia lasting 4 days; Grade 3 or worse febrile neutropenia and thrombopenia (,20 000/mm 3 ); Grade 4 vasculitis, external auditory canal, fatigue, wound infection, ascites (non-malignant), constipation, central nervous system hemorrhage and hyponatremia; Grade 2 or worse middle ear/hearing, pneumonitis/ pulmonary infiltrates and pulmonary fibrosis; and Grade 3 or worse other non-hematological toxicities excepting weight loss, syndrome of inappropriate antidiuretic hormone, anorexia, dyspepsia/heartburn, nausea, vomiting, incontinence and urinary frequency/urgency.
To assess the topotecan dose increase, three patients were enrolled at each dose level and the dose was increased to the next level if none of the patients displayed any DLT. If all the three patients showed DLT, then this dose level was defined as the MTD. If one of the three patients had DLT, an additional three patients were treated at the same level; if none/one of the three additional patients had DLT, the dose was increased to the next level. When two or more of the three additional patients had DLT, this dose level was defined as the MTD. If all the three additional patients showed DLT, the number of additional patients was determined by reference to results of estimation of the doseresponse curve with a continual reassessment method. The recommended dose (RD) for Phase II study was determined to reflect the appearance of toxicity and antitumor effect as the drug dose less than the MTD.
ASSESSMENT OF TREATMENT
Toxicities were assessed according to the US National Cancer Institute Common Toxicity Criteria (NCI-CTC), version 2.0. The severity of other events not listed in the
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Phase I study of topotecan and cisplatin NCI-CTC was graded as follows: Grade 1, slight; Grade 2, moderate; Grade 3, severe; and Grade 4, life threatening. During the study, complete blood cell counts and biochemistry tests were repeated at least twice weekly, whereas other investigations were repeated as needed to evaluate marker lesions. Response was evaluated according to the modified World Health Organization (WHO) criteria (11) .
RESULTS
ESTIMATION OF MTD
Between March 2000 and February 2005, 34 patients were enrolled in this study and all of them received chemotherapy. The characteristics of these patients are shown in Table 1 and the occurrence of DLTs is shown in Table 2 . Gait disturbance occurred on day 10 of the first cycle following Grade 4 neutropenia. Twenty days later, in this patient, a cerebral infarction around the right lateral ventricle was observed by head magnetic resonance imaging diagnosis. This symptom has taken the medical history of cerebral hemorrhage without aftereffect and complications of hyperlipidemia and hyperuricemia into account. Then, this adverse event was observed for recovery tendency. Atrial fibrillation in a patient, who had a history of slight supraventicular arrhythmia without concomitant medication (not conflicted to exclusion criteria), noted at 1.4 mg/m 2 topotecan dose level, appeared just after completion of topotecan administration on day 3 in the first cycle and disappeared by oral anti-arrhythmic agent on the day 4 of the first cycle.
TOXICITIES
All 34 patients of 85 cycles were fully assessable for toxicity. Grade 3/4 toxicities during the overall cycles are summarized in Table 3 . The most common hematological toxicity was neutropenia, followed by thrombocytopenia, leukopenia and anemia. On total comparison between the first cycle and overall cycles in hematological toxicity, at 0.65 mg/m 2 
Non-hematological toxicities
Interference with daily activity
Grade by the National Cancer Institute Common Toxicity Criteria (NCI-CTC). Principal non-hematological toxicities were observed in six cases of nausea and anorexia, three cases of vomiting and interference with daily activity and one case of infection febrile and increased amylase, excluded as DLT events.
CLINICAL RESPONSE
Clinical response is shown in Table 4 . Twelve (63%) of 19 patients in Stage 3 yielded partial response (PR), whereas out of nine patients administered 1 mg/m 2 and more than 1.0 mg/m 2 , seven (78%) showed PR.
RECOMMENDED DOSE
The MTD of topotecan on days 1 -5 for therapy-naive patients in combination with cisplatin on day 1 administration was estimated as 0.65 mg/m 2 . The RD for Phase II was decided as 0.65 mg/m 2 by considering clinical response and toxicity. The MTD of topotecan in the case of cisplatin on day 5 administration was estimated as 1.4 mg/m 2 . The DLTs of this dosage level were atrial fibrillation and gait disturbance in non-hematological toxicity. Since unexpected/ serious non-hematological adverse events were observed at topotecan 1.4 mg/m 2 dose level, the RD was tentatively considered at 1.2 mg/m 2 , in which dose level, no DLT cases were observed. However, after the first course of 1.0 mg/m 2 dose level, frequencies of Grade 3/4 anemia and thrombocytopenia, as hematological toxicities, indicated increased tendency. Thus, the RD for Phase II was decided at 1.0 mg/m 2 , to secure adequate safety.
DISCUSSION
The combination of topotecan and cisplatin has been investigated in several studies. Boabang et al. (5) reported an in vitro study result indicating synergistic antitumor activity between topotecan and cisplatin presumably due to the inhibition of DNA repair mechanisms. Since this drug is categorized as an inhibitor against topoisomerase-I, a previous administration of a DNA-injuring drug seems to be useful (12) . An in vitro combination effect with cisplatin to topotecan was, however, recognized either pre-or postadministration for topotecan. Compared with day 5 administration of cisplatin, day 1 administration indicated an increase in hematotoxicity from the pharmacokinetic mechanism caused by renal dysfunction suspected as subclinical renal tubular damage (10) . From this consideration, a Phase I clinical study in therapy-naive SCLC patients aiming at RD finding was planned from the safety and efficacy of cisplatin day 1 and 5 administration schedules, under the G-CSF concomitant use for the prevention of leukopenia/ neutropenia.
The MTD of topotecan in this study was 0.65 mg/m 2 for cisplatin day 1 administration schedule and 1.4 mg/m 2 for cisplatin day 5 administration schedule. The DLTs which lead these MTDs were hematological toxicities. At the first course, neutropenia was observed at two of six in the cisplatin day 1 administration group and one of three in the day 5 administration scheduled group. One out of six patients in the cisplatin day 1 group also experienced thrombocytopenia. As for neutropenia, the incidence was similar to the DLT in topotecan monotherapy Phase I (7, 13, 14) . In combination therapy of cisplatin and topotecan, the DLT of thrombocytopenia was reported associated with neutropenia (7, 15) . In this study, toxicity data on the second and further courses were also evaluated. In this evaluation, no discrepancy was found between the first course and further courses, which established the DLT in this study as neutropenia and thrombocytopenia.
The non-hematological DLTs were gait disturbance and atrial fibrillation, which were observed in the cisplatin day 5 administration group at 1.4 mg/m 2 of topotecan. No nonhematological DLT was observed in the cisplatin day 1 administration group. Grade 3 non-hematological toxicities of nausea, vomiting, anorexia, fatigue and interference with daily activity were observed as similar to other studies such as topotecan monotherapy and cisplatin combination in which Grade 3/4 non-hematological toxicities of nausea, vomiting, anorexia, fatigue and so on were recorded (7, 13, 15) . These DLTs seem not to be this drug specified from clinical observation on occurrence and progress. Furthermore, no occurrence of Grade 3/4 diarrhea was observed, as different from the similar drug of irinotecan (16) .
The MTDs of Stages 1 and 2 were estimated by taking not only the DLTs during the first cycle but hematological toxicity after the second cycle or further cycles into account. The RD for cisplatin on day 1 schedule was estimated from 
Topotecan ( Overseas, the RD for topotecan monotherapy Phase II in therapy-naive SCLC patients was 1.5 mg/m 2 (14) . The RDs for cisplatin day 1 administration combination were topotecan 0.75 and cisplatin 75 mg/m 2 , respectively (7, 9) . On the other hand, the RDs were reported as topotecan 1.50 or 1.25 mg/m 2 and cisplatin 50 mg/m 2 , respectively, for therapy-naive SCLC in cisplatin day 5 administration schedule (15, 17) . In Japan, the RD of topotecan in monotherapy was 1.0 mg/m 2 . From this study, the RD of topotecan was 65% decreased from monotherapy as 0.65 mg/m 2 in cisplatin day 1 administration schedule and there was no difference from monotherapy in cisplatin day 5 administration schedule. The topotecan RD ratio between cisplatin day 1 administration schedule and day 5 (0.65/1.0) was similar to overseas reports (0.75/1.25 -1.50). Therefore, the RD of topotecan was one half of monotherapy in cisplatin day 1 administration schedule and same or 80% in cisplatin day 5 administration schedule, although cisplatin RD still remains uncertain. The reason for RD reduction in cisplatin day 1 schedule is suspected as the increment of hematotoxicity caused by topotecan clearance decrease by subclinical renal tubular damage (10) .
The dose of combined cisplatin was employed at 60 mg/m 2 as same dose in the case of the similar drug of irinotecan combination (18) . In this study, no DLT occurrence was observed in each three cases of topotecan 1.0 and 1.2 mg/m 2 groups and average administration course numbers were over 3, which indicated the tolerability of this combination. No significant difference in observed toxicities were found compared with monotherapy (19) , and previously conducted topotecan and cisplatin combination clinical studies (7, 9, 15, 17) . These findings suggested the validity of the cisplatin dose of 60 mg/m 2 in this combination. Since neutropenia is DLT in topotecan monotherapy (6) , the prophylactic use of G-CSF was initiated on day 6 of topotecan administration in this study. As the major DLT of this study was, however, neutropenia, the administration timing of G-CSF in this study might not affect the incidence of DLT. According to Saltz et al. (19) , although G-CSF administration did not affect topotecan dose increase, it was suggested that the administration of G-CSF supported prevention against secondary infection or recovery. From safety consideration, the G-CSF concomitant use in this combination seems to be practical.
In conclusion, the RDs of topotecan for 5 consecutive days in combination with 60 mg/m 2 cisplatin in a 3-week cycle were 0.65 mg/m 2 with cisplatin on day 1 with G-CSF and 1.0 mg/m 2 , a maximum of 1.2 mg/m 2 , with cisplatin on day 5 with G-CSF. Further Phase II study of this combination chemotherapy for advanced/metastasis SCLC as firstline therapy is ongoing.
Funding
This work was supported by Nippon Kayaku Co., Ltd.
